Catalent acquires new biologics facility in the UK
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
List view / Grid view
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
Four Big Pharma companies have shared previously unpublished hazard data for drug substances to enhance database-dependent computational tools and help reduce animal testing.
Best estimates suggest counterfeit drugs may account for as much as 50 percent of the sold online and 10 percent of those in circulation worldwide. With counterfeiters primarily replicating packaging to sell imitation products, here Ketaki Badhire of Future Market Insights explores the development of intelligent packaging in combatting counterfeit…
Lentiviral gene therapy reduces infections and bleeding episodes in children with a severe immune disorder Wiskott–Aldrich syndrome (WAS), finds new study.
In a £1.3 million collaborative project Symbiosis and the Cell and Gene Therapy (CGT) Catapult reduced viral vector manufacturing times by more than 25 percent.
Phase III study results show ulcerative colitis patients treated with etrasimod achieved statistically significant improvements in clinical remission compared to placebo.
Lot 31329657B of Teva’s IDArubicin Hydrochloride Injection USP 5mg/5ml vials is being recalled across the US due to particulates.
New pre-clinical research suggests a 24-hour manufacturing process that produces fewer, more potent CAR T cells could be the key to both reducing production timelines and improving patient access to cell therapies.
The results of Eli Lilly and Company’s double-blind, placebo-controlled Phase III trials for Olumiant® are encouraging for patients suffering with alopecia.
To ensure the UK’s prominence in the cell and gene therapy arena, the CGT Catapult has published a roadmap for the research and adoption of these cutting-edge therapies.
The FDA has requested a 2023 budget of $8.4 billion from the US Government, a $2.1 billion increase in funding from 2022.
Researchers demonstrate a simple system using photo-cleavable prodrugs for the precise delivery of cancer treatment in mice.
The March meeting saw the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommend five medications for approval including a multiple myeloma gene therapy.
The new manufacturing facility will support production and development of cannabis-based medicines in the UK.